Astonea Labs

Why is Astonea Labs Ltd falling/rising?

As of 11-Jun, Astonea Labs Ltd's stock price is currently at 232.10, showing a slight increase after a trend reversal following five days of decline. Despite a recent drop over the past week, the stock has performed well over the month and year-to-date, although investor participation has decreased.

As of 11-Jun, Astonea Labs Ltd's stock price is rising, currently at 232.10, reflecting a change of 0.6 (0.26%) upward. This increase comes after a trend reversal, as the stock has gained following five consecutive days of decline. Despite a significant drop of 17.70% over the past week, the stock has shown strong performance over longer periods, with a 36.53% increase over the past month and a remarkable 41.96% rise year-to-date. <BR><BR>The stock's current price is above the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in the longer term, although it is below the 5-day moving average. However, there has been a noted decrease in investor participation, with delivery volume falling by 42.86% against the 5-day average, which could suggest a cautious sentiment among investors. Despite this, the stock remains liquid enough for trading, which may support its current upward movement. Overall, the combination of a recent trend reversal and strong long-term performance contributes to the stock's rising price.

What does Astonea Labs do?

Astonea Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated in 2017 and rebranded in 2024. It currently has no available revenue or profit data, with a market cap of INR 255 Cr and a P/E ratio of 54.00.

Overview:<BR>Astonea Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Astonea Labs Limited was originally incorporated as "AHU Laboratories Private Limited" in 2017. The company changed its name to "Astonea Labs Private Limited" on February 26, 2019, and subsequently to "Astonea Labs Limited" on January 11, 2024. Revenue and profit data are not available for any reporting period.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 255 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 54.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.75<BR>Return on Equity: 7.91%<BR>Price-to-Book: 4.47<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

Which are the latest news on Astonea Labs?

How big is Astonea Labs?

Summary could not be generated.

As of 10th June, Astonea Labs Ltd has a market capitalization of 255.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest annual period reported is March 2025, with Shareholder's Funds amounting to 18.41 Cr and Total Assets valued at 103.38 Cr.

Who are the peers of the Astonea Labs?

Astonea Labs' peers include Medicamen Biotec, Trident Lifeline, Zenotech Lab., Lyka Labs, Everest Organics, Ambalal Sarabhai, Gennex Lab., BDH Industries, and Sat Kartar. Astonea Labs has the highest 1-year return at 58.56%, while Medicamen Biotec has the lowest at -46.53%.

Peers: The peers of Astonea Labs are Medicamen Biotec, Trident Lifeline, Zenotech Lab., Lyka Labs, Everest Organics, Ambalal Sarabhai, Gennex Lab., BDH Industries, and Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sat Kartar, while Average management risk is found at Medicamen Biotec, Trident Lifeline, Zenotech Lab., Lyka Labs, Astonea Labs, Everest Organics, Gennex Lab., and the rest. Below Average management risk is noted at Ambalal Sarabhai and Infinium Pharma. Growth is Excellent at Trident Lifeline and Sat Kartar, Good at Gennex Lab., Zenotech Lab., and Astonea Labs, while Below Average growth is seen at Medicamen Biotec, Lyka Labs, Everest Organics, and the rest. Capital Structure is Excellent at Medicamen Biotec, Zenotech Lab., Gennex Lab., and BDH Industries, Good at Trident Lifeline, Average at Ambalal Sarabhai, and Below Average at Astonea Labs, Lyka Labs, Everest Organics, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Astonea Labs at 58.56%, while the lowest is Medicamen Biotec at -46.53%. Astonea Labs' return is significantly higher than all its peers. Additionally, Everest Organics, Ambalal Sarabhai, Gennex Lab., and Infinium Pharma have negative six-month returns.

When is the next results date for Astonea Labs Ltd?

The next results date for Astonea Labs Ltd is 30 May 2026.

The next results date for Astonea Labs Ltd is scheduled for 30 May 2026.

Is Astonea Labs overvalued or undervalued?

As of August 28, 2025, Astonea Labs is considered very expensive with a PE ratio of 34.32, significantly higher than its peers, indicating overvaluation and underperformance, as it has declined 3.48% recently compared to a 2.34% drop in the Sensex.

As of 28 August 2025, Astonea Labs' valuation grade has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 34.32, a Price to Book Value of 15.34, and an EV to EBITDA of 14.93. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Astonea Labs' PE ratio is higher than Sun Pharma's 33.18 and significantly above Cipla's attractive PE of 23.65. The PEG ratio of Astonea Labs stands at 0.00, which is unusual and raises concerns about future growth expectations. Recent stock performance shows a decline of 3.48% over the past week, while the Sensex fell only 2.34%, reinforcing the notion that Astonea Labs is not only overvalued but also underperforming relative to the broader market.

How has been the historical performance of Astonea Labs?

Astonea Labs has shown gradual profitability improvement over the past three years, with a profit before tax rising from 0.00 Cr in March 2022 to 5.00 Cr in March 2024. Cash flow from operating activities turned positive at 4.00 Cr in March 2024, while cash flow from investing activities remained negative.

Answer:<BR>The historical performance of Astonea Labs shows a gradual improvement in profitability over the past three years, despite the absence of standalone annual results and balance sheet data.<BR><BR>Breakdown:<BR>In the cash flow results, Astonea Labs reported a profit before tax of 5.00 Cr in March 2024, a significant increase from 1.00 Cr in March 2023 and up from 0.00 Cr in March 2022. Adjustments remained stable at 6.00 Cr for both March 2024 and March 2023, while it was slightly lower at 5.00 Cr in March 2022. Changes in working capital showed a decrease in negative values, with -7.00 Cr in both March 2024 and March 2023, compared to -10.00 Cr in March 2022. Consequently, cash flow after changes in working capital improved to 4.00 Cr in March 2024, up from 0.00 Cr in March 2023 and a negative 4.00 Cr in March 2022. Cash flow from operating activities also turned positive at 4.00 Cr in March 2024, contrasting with -1.00 Cr in March 2023 and -4.00 Cr in March 2022. However, cash flow from investing activities was negative, amounting to -7.00 Cr in March 2024, compared to -3.00 Cr in the previous two years. Cash flow from financing activities decreased to 3.00 Cr in March 2024 from 4.00 Cr in March 2023 and 8.00 Cr in March 2022. Overall, the net cash inflow/outflow remained at 0.00 Cr for all three years, indicating no change in cash position.

Who are the top shareholders of the Astonea Labs?

Astonea Labs is primarily owned by its promoters, who hold the majority of shares with no pledged holdings. There are no mutual funds, foreign institutional investors, or notable individual public shareholders involved.

Astonea Labs is primarily owned by its promoters, who hold the majority of the shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no notable individual investors or public shareholders listed. This indicates a concentrated ownership structure primarily focused within the promoter group.

Has Astonea Labs declared dividend?

No Dividend History Available